FDA grants priority review to Genentech’s MS drug
CAR T-Cell Therapy Achieves Lasting Remission in Child’s Liver Cancer
Pharmacies must balance trust with digital convenience
September 22, 2026
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
September 18, 2026
Adjuvant Osimertinib Shows 8-Year Survival Benefit in Lung Cancer
September 16, 2026
Ivonescimab improves survival over pembrolizumab in advanced lung cancer
September 15, 2026
Doctor Dispatches ❖ FEATURED
Experts Offer Mentorship Advice for New Neurologists
Doctor Dispatches ❖ FEATURED
Pharmacists fill vaccination gap as measles cases surge
Doctor Dispatches ❖ FEATURED
Clinics recruit future medical administrators
Doctor Dispatches ❖ FEATURED
Air crews face higher cancer death risk
New study tests direct switch from IVIG to subcutaneous efgartigimod
New International Study Monitors Nipocalimab Use in Pregnancy
The PETUNIA study tracks nipocalimab pregnancy outcomes, monitoring pregnant people with myasthenia gravis, presented at the 2026 AANEM meeting.
October 1, 2026
FDA delays review of rare epilepsy drug
The FDA delays review of relutrigine, an experimental treatment for SCN2A/SCN8A-related epilepsy, pushing the decision date to December 27, 2026.
September 28, 2026
FDA approves first treatments for rare ataxia disorders
The FDA has approved the first treatments for rare ataxia disorders, including Omaveloxolone for Friedreich ataxia and levacetylleucine for ataxia-telangiectasi
September 26, 2026
Monocytes predict vaccine side effects
Monocytes may predict vaccine side effects in individuals after receiving an mRNA vaccine.
September 21, 2026
Dapagliflozin Reduces Heart Failure Risks, Regardless of Congestion
Dapagliflozin reduces heart failure risks regardless of congestion, according to the DAPA ACT HF-TIMI 68 trial.
September 19, 2026
Sotatercept Added to PAH Treatment Guidelines
Sotatercept is added to PAH treatment guidelines as an additional therapy for patients.
September 17, 2026
New lung cancer drug dosing shows promise for patient convenience
Cancer rates rise among 9/11 survivors
MedTech Devices Evolve, Pushing Materiovigilance Ahead
Wellness Rounds
Trappsol Cyclo trial misses primary goal, subgroup benefits
Wellness Rounds
Inebilizumab shows benefit in myasthenia gravis patients
Wellness Rounds
AI tools improve medical device safety checks
MedTech firms advance lean manufacturing techniques
MedTech firms are revolutionizing lean manufacturing with digital integration and precision techniques for medical device production.
September 7, 2026
Pharmacist Publishes Guide to Pass PEBC Exam
The PEBC exam guide by pharmacist Michael Kani offers strategies to boost pass rates, shifting focus from memorization to clinical…
September 3, 2026
U of A offers AI, health, population certificates
U of A launches an AI health certificate and population health credential for health professionals, tackling workforce shortages and fast…
August 30, 2026
Latest News
Trappsol Cyclo trial misses primary goal, subgroup benefits
Trappsol Cyclo trial missed primary goal in Niemann-Pick disease, but subgroup benefits show signs of slowing disease progression…
By Nadia Yusof October 3, 2026
New study tests direct switch from IVIG to subcutaneous efgartigimod
New phase 4 study explores direct switch from IVIG to subcutaneous efgartigimod for CIDP patients without disease worsening,…
By Nadia Yusof October 2, 2026
New International Study Monitors Nipocalimab Use in Pregnancy
The PETUNIA study tracks nipocalimab pregnancy outcomes, monitoring pregnant people with myasthenia gravis, presented at the 2026 AANEM…
By Aliya Hassan October 1, 2026
FDA grants priority review to Genentech’s MS drug
The FDA granted priority review to fenebrutinib multiple sclerosis drug, an experimental BTK inhibitor that may treat relapsing…
By E Hughes September 30, 2026
Inebilizumab shows benefit in myasthenia gravis patients
Inebilizumab shows benefit in myasthenia gravis patients with sustained clinical progress.
By E Hughes September 29, 2026
FDA delays review of rare epilepsy drug
The FDA delays review of relutrigine, an experimental treatment for SCN2A/SCN8A-related epilepsy, pushing the decision date to December…
By E Hughes September 28, 2026
FDA approves first treatments for rare ataxia disorders
The FDA has approved the first treatments for rare ataxia disorders, including Omaveloxolone for Friedreich ataxia and levacetylleucine…
By Nadia Yusof September 26, 2026
Experts Offer Mentorship Advice for New Neurologists
Experts Blake Buletko and Galina Gheihman discuss neurologist mentorship advice for new doctors transitioning to practice. Explore essential…
By E Hughes September 25, 2026
FDA Grants Fast Track Status to Apitegromab
FDA grants fast track status to apitegromab for muscular dystrophy treatment, showing urgency in advancing new treatments.
By Aliya Hassan September 24, 2026
CAR T-Cell Therapy Achieves Lasting Remission in Child’s Liver Cancer
CAR T-cell therapy achieves lasting remission in a child's liver cancer, offering hope for chemotherapy-resistant cases.
By Aliya Hassan September 23, 2026